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Epigenetics is defined as heritable changes in gene ex-
pression that are not linked to changes in the DNA se-
quence. Epigenetic events are one of the important mecha-
nisms that regulate the differentiation of different types of
cells during both prenatal and postnatal development. The
major epigenetic mechanisms that affect gene expression are
histone modification, genomic DNA methylation, and activi-
ties of noncoding RNAs (Gibney & Nolan, 2010). Histone
modifications via two distinctive enzymes histone acetyl-
transferases (HATs) and histone deacetylases (HDACs) in-
volve different mechanisms of histone substrate binding and
catalysis (Buchwald, et al., 2009 ; de Ruijter, et al., 2003).
Histone acetylation is generally associated with transcrip-
tional activation, whereas deacetylation of histones represses
gene expression. DNA methylation plays an important role
via the addition of a methyl group to the 5th carbon of cyto-
sine in the CpG dinucleotide sequence during DNA repair,
recombination, and replication (Chin, et al., 2011). A non-
coding RNA (ncRNA) is a functional RNA molecule that is
transcribed from DNA, but not translated into a protein. The
epigenetic related ncRNAs include miRNA, siRNA, piRNA
and lncRNA (Peschansky & Wahlestedt, 2014).
A greater understanding of the epigenetic events in bone
cells could help improve tissue engineering strategies in the
bone and identify novel anabolic targets. Recently, several
types of histone deacetylase inhibitors (HDACis) have been
used to induce calcification and promote osteogenesis. How-
ever, variations in the results of these studies exist, and a
consensus on the usefulness of HDACis has not been
reached thus far (Haberland, et al., 2009). In this review, we
summarized on the effectiveness of several types of HDACis
on osteogenesis and discussed the possibility of using them
in the clinical setting.
Histone deacetylases ( HDACs ) and histone
deacetylase inhibitors (HDACis)
The acetylation of histone proteins is a balance between
the activities of both HATs and HDACs. HDACs with his-
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Abstract
The major epigenetic mechanisms affecting gene ex-
pression are histone modifications, DNA methylation,
and activities of noncoding RNAs. Histone modifica-
tions by two distinctive enzymes histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs) dis-
play different mechanisms of histone substrate binding
and catalysis, and affect gene transcriptions. Recently,
HDAC inhibitors (HDACis) that increase acetylation of
histones have been clinically applied for certain types
of diseases including cancer, epilepsy, bipolar disorder,
and blood diseases. Although HDAC is controlled os-
teogenesis both in vitro and in vivo, no clinical applica-
tion of HDACi for bone regeneration has been per-
formed. This review introduces how HDACis affect
bone regeneration in vitro and in vivo. Certain types of
HDACis may be clinically useful for bone regeneration.
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tone acetylation are generally associated with an increase in
gene transcription, whereas deacetylation results in decreased
gene transcription. Eighteen HDACs have been identified in
humans, and are divided into four subclasses based on the
homology to the yeast genes as follows : class I (HDAC1,
HDAC2, HDAC3, and HDAC8), class IIa (HDAC4, HDAC
5, HDAC7, and HDAC9), class IIb (HDAC6 and HDAC10),
class III (sirtuin [SIRT1] to −7), and class IV (HDAC11)
(Haberland, et al., 2009). HDACs often induced pathogenic
transcriptions ; therefore their inhibition might prove useful
for the treatment of various diseases (Chuang, et al., 2009).
HDACis have been chemically synthesized and applied for
the treatment of psychiatric and neurological diseases (van
Bokhoven H. , 2011 ) . In addition, several classes of
HDACis, including hydroxamic acids, cyclic peptides, bu-
tyrates, and benzamides have been discovered (Yoshida, et
al., 1990 ; Komatsu, et al., 2001 ; Candido, et al., 1978). The
hydroxamates include vorinostat, givinostat, abexinostat,
panobinostat, belinostat, and the prototypical HDACi,
trichostatin A ( TSA ) . The cyclic peptides include com-
pounds such as depsipeptide and troponin, whereas the ben-
zamides include entinostat ( MS − 275 ) , and mocetinostat.
Some of these HDACis have been approved for use as phar-
maceutical drugs (Jones, et al., 2016).
Involvement of HDACs in bone development
Bone development is a dynamic and complex process that
requires precise control of the transcriptional events in multi-
ple cell types, and is sensitive to changes in HDACs levels
(Dudakovic, et al., 2013). HDACs play important roles in
maintaining the balance between osteoblastic bone formation
and osteoclastic bone resorption, processes that are crucial
for bone tissue homeostasis (Destaing, et al., 2005). The cru-
cial roles of several HDACs in both intramembranous and
endochondral bone development are shown in Table 1.
a. Class I HDACs ( HDAC 1, HDAC 2, HDAC 3, and
HDAC8)
The roles of HDACs in bone development have been
evaluated mainly by the genetic deletion of each HDAC
(Schroeder & Westendorf, 2005). Class I HDACs are essen-
tial regulators for both intramembrane and endochondral
bone development. Targeted deletion of HDAC1 is lethal re-
sulting in severe proliferation defects and retardation in de-
velopment (Lagger, et al. , 2002 ; Trivedi, et al. , 2007 ) .
Germline deletion of HDAC2 has partialy embryonic lethal-
ity, and causes significant decreases in body size and long
bone length as a result of abnormal endochondral ossifica-
tion (Trivedi, et al., 2007). HDAC1 and HDAC2 inhibit os-
Class HDACs Targeted protein Protein expression Mode of action Terminal bone phenotype References
I
HDAC1 RUNX2 ↓ Inhibition of osteoblast differentia-
tion
Severe proliferation defects and retar-
dation in bone development
Lagger, et al., 2002
HDAC2
RUNX2 ↓ Inhibition of osteoblast differentia-
tion Reduced body size and long bone
length
Lee, et al., 2006
Dou, et al., 2016
FoxO1 ↓ Increased osteoclastogenesis
HDAC3 RUNX2 ↓




Severe endochondral bone defects
Severe craniofacial malformations in
skull
Singh, et al., 2013
Schroeder et al., 2004
HDAC8 Otx2 and Lhx1 ↑ Decreased intramembranous ossifi-
cation
Ossification defects in frontal bone Haberland, et al., 2009
II
HDAC4 RUNX2 ↓ Premature endochondral ossification
by repressing transcriptional activity
Skeletal defects and premature skull
ossification
Vega, et al., 2004
HDAC5 RUNX2 ↓ Suppression of osteoblast differen-
tiation
Reduced trabecular bone density
Juvenile osteoporosis
Obri, et al., 2014
Kang, et al., 2005
HDAC6 RUNX2 ↓ Cytoskeletal changes in osteoclasts
and bone resorption
Increased cancellous bone density
Westendorf, et al.., 2002
Zhang, et al., 2008
HDAC7 RUNX2 ↓
Regulation of endochondral ossifica-
tion by deacetylation− independent
manner
Reduced femur lengths, and decreased
trabecular bone density
Jensen, et al., 2008
Bradley, et al., 2015
III
Sirt1 NA NA
Osteoblast differentiation of mesen-
chymal stem cells
Developmental defects, including
shorter stature, craniofacial abnormali-
ties, increased cartilage apoptosis
Reduced endochondral ossification
Bradley, et al., 2015
Cheng, et al., 2003
Backesjo, et al., 2006
Sirt6 NA NA
Facilitates endochondral ossification
by controlling chondrocyte prolif-
eration and differentiation
Bone growth retardation Mostoslavsky, et al., 2006
Table 1 : Role of histone deacetylases (HDACs) in bone development
HDAC : Histone deacetylase ; RUNX2 : Runt−related transcription factor 2 ;↑ : Up regulation ;↓ : Down regulation ; Otx2 : Orthodenticle homeobox 2 ; Lhx1 :
LIM homeobox 1 ; Sirt : Sirtuin ; NA : Not applicable.
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teoblast differentiation via down−regulation of the Runt−re-
lated transcription factor2 (Runx2) , a key factor for os-
teoblast differentiation (Lagger, et al. , 2002 ; Lee, et al. ,
2006 ) . HDAC 2 also inhibits Forkhead box protein O 1
(FoxO1), a negative regulator of osteoclast differentiation to
promote osteoclastogenesis (Dou, et al., 2016). Furthermore,
germline deletion of HDAC3 has been shown to cause early
embryonic lethality (Montgomery, et al. , 2008) , whereas,
HDAC3 suppression caused severe endochondral bone de-
fects due to decreased amount of cartilage matrix formation,
fewer osteoblasts, and poor cortical as well as trabecular
bone architecture in animals (Bradley, et al., 2013 ; Razidlo,
et al. , 2010). HDAC3 is also involved in intramembrane
bone development. Loss of HDAC3 in the neural crest cells
resulted in severe craniofacial malformations, including mi-
crocephaly, cleft palate, impaired bone formation in the
skull, and hypoplasia of the teeth (Singh, et al., 2013). Simi-
larly, HDAC3 conditional knockout mice in osterix−express-
ing progenitor cells resulted decreases in calvarial bone
thickness and density (Razidlo, et al., 2010). The global de-
letion of the HDAC8 gene in mice leads to perinatal lethal-
ity due to altered cranial and facial features, and this is phe-
nocopied by the conditional deletion of HDAC8 in cranial
neural crest cells (Haberland, et al., 2009). Both, HDAC3
and 8 are transcriptional co−repressors of several transcrip-
tion factors ; therefore, the suppression of HDAC 3 in
preosteoblasts reduces matrix mineralization and the expres-
sion levels of several genes that target Runx2 (Schroeder et
al., 2004). HDAC8 represses the aberrant expression of ho-
meobox transcription factors, specifically, orthodenticle ho-
meobox 2 (Otx2) and LIM homeobox 1(Lhx1), essential for
proper head development (Haberland, et al., 2009). Taken
together, HDAC1, 2, and 3 play important roles in bone de-
velopment via Runx2 activation. HDAC8 contributes to nor-
mal bone formation via its inhibitory effect on the aberrant
expression of homeobox proteins.
b. Class II HDACs ( HDAC 4, HDAC 5, HDAC 6, and
HDAC7)
Class II HDACs mainly contribute to endochondral bone
development. Unlike the class I HDACs, germline deletion
of most class II HDACs does not cause embryonic lethality
but results in some level of functional redundancy. HDAC4
deficiency leads to premature endochondral ossification re-
sulting in skeletal defects such as vertebrae body fusion, de-
crease in the length of the long bone, and premature skull
ossification (Vega, et al., 2004). Although HDAC5 knockout
mice showed no abnormal structures or growth defects, they
presented with reduced trabecular bone density at 2 − 3
months of age, despite modest increases in the rates of bone
formation ( Obri, et al. , 2014 ) . The genetic deletion of
murine HDAC6 modestly increased the density of the can-
cellous bone (Zhang, et al., 2008 ; Westendorf, et al., 2002).
Postnatal deletion of HDAC 7 in the same population of
chondrocytes led to an expansion of the proliferative zone,
narrowing of the hypertrophic zone, reduction in femur
lengths, and decrease in trabecular bone density (Bradley, et
al., 2015a). Class II HDACs have low intrinsic deacetylase
activity and work through functional complexes involving a
class I HDAC. All class II HDACs have been shown to
deacetylase Runx2 thereby, repressing its transcriptional ac-
tivity, decreasing osteoblast differentiation, and promoting
osteoclastogenesis (Table 1) (Kang, et al. , 2005 ; Westen-
dorf, et al., 2002 ; Jensen, et al., 2008).
c. Class III HDACs (Sirt1 and Sirt6)
Class III HDACs, Sirt1 and Sirt6, play important roles in
endochondral ossification. The activation of Sirt1 in mesen-
chymal stem cells promotes osteogenic differentiation, essen-
tial for endochondral ossification ( Barter, et al. , 2012 ) .
Germline Sirt1 deficiency increased p53−mediated apoptosis
and produced severe developmental defects, including
shorter stature, craniofacial abnormalities, increased cartilage
apoptosis, and reduced endochondral ossification and corti-
cal thickness in mice (Cheng, et al., 2003). Sirt6 facilitates
endochondral ossification by controlling chondrocyte prolif-
eration and differentiation. Sirt6 knock out mice displayed
growth retardation shortly after birth, failed to thrive, and
died at around 3.5 weeks of age due to genomic instability
and degeneration of multiple organs (Mostoslavsky, et al.,
2006). Although Sirt1 and Sirt6 have been shown to play
important roles in bone development, the involvement of the
other types of Sirts remains to be elucidated.
Involvement of histone deacetylase inhibitors
(HDACis) in osteogenesis
HDACis affect many cellular properties, such as the cell
cycle, Progression proliferation rates, gene expression, dif-
ferentiation potential, accumulation of reactive oxygen spe-
cies, and changes in cell death pathways ( Khan & La
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Thangue, 2012 ; Conte & Altucci, 2012 ; Dawson & Kou-
zarides, 2012). Attempts to apply HDACis for the regenera-
tion of different tissues, such as cardiac, neural / nervous,
dental, liver, and cartilaginous tissues, have been made (Oh-
tani & Dimmeler, 2011 ; Hsieh, et al., 2004 ; Duncan, 2011,
2012 ; Kurinna, et al., 2011 ; Hong, et al., 2009). Among
them, the involvement of HDACis in bone regeneration is
well documented (Boer, et al. , 2006 ; Cho et al. , 2005 ;
Huynh et al., 2016, 2017). The osteogenic differentiation of
different cell types is accelerated by several types of
HDACis including sodium butyrate ( NaB ) , valproic acid
(VPA), trichostatin A (TSA), suberoylanilide hydroxamic
acid (SAHA), and Benzamide (MS−275) (Fig. 1 ; Table 2).
NaB promoted osteoblast bone formation by enhancing the
activities of Runx2 and ALP in vitro (Iwami & Moriyama,
1993) ; the effects of NaB on the osteoblastic cell line and
periodontal ligament fibroblast were reported for the first
time in this study. Similarly, VPA and TSA enhanced osteo-
genic differentiation with the upregulation of several os-
teoblast marker genes (Lee, et al., 2006, 2009 ; Cho, et al.,
2005 ; Xu, et al., 2009, 2013 ; Jeon, et al., 2006). SAHA,
another pan HDACi, promoted mineralization and migration
in primary osteoblasts by inducing the expression and activ-
ity of metalloproteinase (MMP)−13 (Duncan, et al., 2016).
In addition, MS−275 has been found to stimulate bone for-
mation by inducing the transcription of tissue−nonspecific
alkaline phosphatase (TNAP) (Kim, et al., 2011). Together,
these data indicate that the suppression of HDAC activity
with these HDACis sufficiently promote the osteogenic dif-
ferentiation of several cells via the upregulation of various
transcription−related proteins, which may distinct roles dur-
ing this process.
Fig 1 : Schematic representation showing role of HDACis on several cells for osteogenesis
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Possible clinical applications of histone deace-
tylase inhibitors (HDACis) for bone regenera-
tion
To date, four HDACis have been approved by the United
States Food and Drug Administration (US FDA) for the fol-
lowing anti − cancer drugs : Vorinostat, Romidepsin, Beli-
nostat, and Panobinostat. Vorinostat (SAHA ; trade name,
ZolinzaⓇ) is a linear hydroxamate compound that was ap-
proved for the treatment of cutaneous T − cell lymphoma
(CTCL) (Mann, et al., 2007). Romidepsin (FK228 or dep-
sipeptide ; trade name, IstodaxⓇ) is a cyclicpeptide HDACi
that was originally approved for the treatment of CTCL by
the US FDA ; subsequently, its use was extended for the
treatment of peripheral T−cell lymphoma (PTCL) (Whit-
taker, et al., 2010). A third FDA approval was given for the
HDACi Belinostat ( PXD 101 ; trade name, BeleodaqⓇ ) ,
which is a hydroxamic acid compound licensed for the treat-
ment of relapsed or refractory PTCL. Like the other two
FDA−approved HDACis, Belinostat is in the clinical trial
phase for solid tumors (Poole, 2014). Panobinostat (LBH−
589 ; trade name, FarydakⓇ) is the most recently approved
HDACi (Oki, et al., 2013) and was licensed for the treat-
ment of multiple myeloma. Additionally, more than five
HDACis are in phase III clinical trials, including reposition-
ing of already approved HDACis (Jeon, et al., 2006). In ad-
dition to cancer treatment, the use of HDACis has been
evaluated in various non−cancer diseases including neurode-
generative disease, inflammatory disease, osteoporosis, car-
diovascular disease, HIV, and neurological diseases (Choi &
Mostoslavsky, 2014 ; Dinarello, et al., 2011 ; Falkenberg &
Johnstone, 2014 ; Lakshmaiah, et al., 2014). Some HDACis
have been used for the treatment of experimentally−induced
osteoporosis and fractures, and have successfully promoted
bone regeneration in animal models (Boer et al. , 2006 ;
McGee−Lawrence & Westendorf, 2011). Thus, they may be
applied for bone regeneration as a clinically secure drug.
Conclusion
Recently, it has been demonstrated that HDACis can im-
prove tissue engineering strategies. Bone tissue engineering
has found early success in studies combining mesenchymal
stem cells (MSCs) with HDACis ; therefore, there is a poten-
tial to translate this research into the clinical settings. Pres-
ently, researchers aim to combine scaffolds with growth fac-
tors, suitable cells, and environmental stimuli to generate
functional tissue, such as bone and dentin in hard tissue re-
generation region. This review shows that HDACis could be
utilized as chemical cues to improve the efficacy of current
tissue engineering techniques.
Inhibitor Targeted cell Mechanism of action Effect References
NaB
Cloned osteoblastic cell lines
Periodontal ligament fibroblasts
Increased ALP activity Enhancement of bone formation Iwami & Moriyama, 1993
Primary bone marrow cells
Rat osteosarcoma cells
Calvaria cells
Increased the expression of Runx2, OC
and ALP
Osteogenesis Lee, et al, 2006, 2009
Adipose−derived stromal cells Decreased oxygen tension Osteogenesis Xu, et al., 2009
VPA
Adipose cells
Bone marrow stromal cells
Increased the expression of Runx 2,
OSX, OPN, BMP2 and ALP
Osteogenic differentiation
Cho, et al., 2005
Jeon, et al., 2006
Adipose−derived stromal cells Decreased oxygen tension Osteogenesis Xu, et al., 2009
Dental pulp stem cells Increase OC, BSP, OPN Osteogenesis Shen, et al., 2002
TSA
Primary bone marrow cells
Rat osteosarcoma cells
Calvaria cells
Increased the expression of Runx2, OC
and ALP
Osteogenesis Lee, et al, 2006, 2009
Bone marrow stromal cells
Increased the expression of Runx2 and
ALP
Osteogenic differentiation Cho, et al., 2005
Human periodontal ligament cells Increased the expression of Runx2
Osteogenesis and enhanced mineral
deposition
Huynh, et al., 2016
SAHA Primary osteoblasts Increased MMP−13 Osteogenesis Duncan, et al., 2016
MS−275 Primary osteoblast precursors Increased TNAP Osteoblast bone formation Kim, et al., 2011
Table 2 : The role of HDAC inhibitors (HDACis) on osteogenesis
NaB : sodium butyrate ; VPA : valproic acid ; TSA : Trichostatin A ; SAHA : suberoylanilide hydroxamic acid ; MS−275 : benzamide ; ALP : alkaline phosphatase ;
Runx2 : runt−related transcription factor 2 ; OC : osteocalcin ; OSX : osterix ; OPN : osteopontin ; BMP2 : bone morphogenetic protein 2 ; BSP : bone sialoprotein ;
MMP−13 : matrix metallopeptidase ; TNAP : tissue−nonspecific alkaline phosphatase.
35The Dental Journal of Health Sciences University of Hokkaido 39 2020
（35）
第３９巻１号　　　４Ｃ１５０　１Ｃ１３３／本文　※３１‐１から組体裁変更　ＯＴＦ／０３１～０３９　レビュ　ＳＵＬＴＡ　４Ｃ  2020.07.22 11.01.03  Page 35 
References
Barter MJ, Bui C & Young DA. Epigenetic mechanisms in
cartilage and osteoarthritis : DNA methylation, histone
modifications and microRNAs. Osteoarthritis Cartilage 20
(5) : 339−349, 2012.
Boer J, Licht R & Bongers M. Inhibition of histone ace-
tylation as a tool in bone tissue engineering. Tissue Eng.
12 : 2927–2937, 2006.
Bradley EW, Carpio LR & Westendorf JJ. Histone deacety-
lase 3 suppression increases PH domain and leucine−rich
repeat phosphatase (Phlpp) 1 expression in chondrocytes
to suppress Akt signaling and matrix secretion. J Biol
Chem 288 : 9572–9582, 2013.
Bradley EW, Carpio LR, Olson EN & Westendorf JJ. His-
tone deacetylase 7 (Hdac7) suppresses chondrocyte prolif-
eration and beta−catenin activity during endochondral os-
sification. J Biol Chem 290 : 118–126, 2015.
Buchwald M, Kramer OH & Heinzel T. HDACi–targets
beyond chromatin. Cancer Lett 280(2) : 160−167, 2009.
Candido EP, Reeves R & Davie JR. Sodium butyrate in-
hibits histone deacetylation in cultured cells. Cell 14(1) :
105−113, 1978.
Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Pa-
tel P, Bronson R, Appella E, Alt FW &Chua KF. Devel-
opmental defects and p53 hyperacetylation in Sir2 ho-
molog (SIRT1)−deficient mice. Proc Natl Acad Sci 100 :
10794–10799, 2003.
Chin SP, Dickinson JL & Holloway AF. Epigenetic regula-
tion of prostate cancer. Clin Epigenet 2 (2) : 151−169,
2011.
Cho HH, Park HT, Kim YJ, Bae YC, Suh KT & Jung JS.
Induction of osteogenic differentiation of human mesen-
chymal stem cells by histone deacetylase inhibitors. J Cell
Biochem 96(3) : 533–542, 2005.
Choi JE & Mostoslavsky R. Sirtuins, metabolism, and
DNA repair. Curr Op in Genet Dev 26C : 24 –32, 2014.
Chuang DM, Leng Y, Marinova Z, Kim HJ & Chiu CT.
Multiple roles of HDAC inhibition in neurodegenerative
conditions. Trends Neurosci 32(11) : 591−601, 2009.
Conte M & Altucci L. Molecular pathways : the complexity
of the epigenome in cancer and recent clinical advances.
Clin Cancer Res, 18 : 5526−5534, 2012.
Dawson MA & Kouzarides T. Cancer epigenetics : from
mechanism to therapy. Cell 150(1) : 12−27, 2012.
Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S,
Ory S & Jurdic P. A novel Rho−mDia2−HDAC6 pathway
controls podosome patterning through microtubule ace-
tylation in osteoclasts. J Cell Sci 118 (13) : 2901–2911,
2005.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S & van
Kuilenburg AB. Histone deacetylases (HDACs) : charac-
terization of the classical HDAC family. Biochem J 370 :
737−749, 2003.
Dinarello CA, Fossati G & Mascagni P. Histone deacety-
lase inhibitors for treating a spectrum of diseases not re-
lated to cancer. Mol Med 17 : 333–352, 2011.
Dou C, Li N, Ding N, Liu C, Yang X, Kang F, Cao Z,
Quan H, Hou T, Xu J & Dong S. HDAC2 regulates FoxO
1 during RANKL − induced osteoclastogenesis. Am J
Physiol Cell Physiol 310(10) : C780−7, 2016.
Dudakovic A, Evans JM, Li Y, Middha S, McGee−Law-
rence ME, van Wijnen AJ, Westendorf JJ. Histone deace-
tylase inhibition promotes osteoblast maturation by alter-
ing the histone H4 epigenome and reduces Akt phospho-
rylation. J Biol Chem 288(40) : 28783−91, 2013.
Duncan HF, Smith AJ, Fleming GJ & Cooper PR.
HDACi : cellular effects, opportunities for restorative den-
tistry. J Dent Res 90 : 1377–1388, 2011.
Duncan HF, Smith AJ, Fleming GJP & Cooper PR. His-
tone deacetylase inhibitors induced differentiation and ac-
celerated mineralization of pulp derived cells. J Endod
38 : 339–345, 2012.
Duncan HF, Smith AJ, Fleming GJ, Partridge NC, Shimizu
E, Moran GP, Cooper PR. The histone−deacetylase−in-
hibitor suberoylanilide hydroxamic acid promotes dental
pulp repair mechanisms through modulation of matrix
metalloproteinase−13 activity. J Cell Physiol 231 (4), 798
–816, 2016.
Falkenberg KJ & Johnstone RW. Histone deacetylases and
their inhibitors in cancer, neurological diseases and im-
mune disorders. Nat Rev Drug Discov13 : 673–691, 2014.
Gibney ER & Nolan CM. Epigenetics and gene expression.
Heredity 105 : 4−13, 2010.
Haberland M, Mokalled MH, Montgomery RL & Olson
EN. Epigenetic control of skull morphogenesis by histone
deacetylase 8. Genes Dev 23 : 1625–1630, 2009.
Hong S, Derfoul A, Pereira−Mouries L & Hall D J. A
novel domain in histone deacetylase 1 and 2 mediates re-
pression of cartilage−specific genes in human chondro-
36 Shamima SULTANA et al.／Histone deacetylases and their inhibitors (HDACis) for bone formation and regeneration : A review
（36）
第３９巻１号　　　４Ｃ１５０　１Ｃ１３３／本文　※３１‐１から組体裁変更　ＯＴＦ／０３１～０３９　レビュ　ＳＵＬＴＡ　４Ｃ  2020.07.22 11.01.03  Page 36 
cytes. FASEB J 23, 3539–3552, 2009.
Hsieh J, Nakashima K, Kuwabara T, Mejia E & Gage FH.
Histone deacetylase inhibition− mediated neuronal differ-
entiation of multipotent adult neural progenitor cells. Proc
Natl Acad Sci 101, 16659–16664, 2004.
Huynh NC, Everts V, Pavasant P & Ampornaramveth RS.
Inhibition of histone deacetylases enhances the osteogenic
differentiation of human periodontal ligament cells. J Cell
Biochem 117(6) : 1384−1395, 2016.
Huynh NC, Everts V, Nifuji A, Pavasant P & Ampor-
naramveth RS. Histone deacetylase inhibition enhances in
−vivo bone regeneration induced by human periodontal
ligament cells. Bone 95 : 76−84, 2017.
Iwami K & Moriyama T. Effects of short chain fatty acid,
sodium butyrate, on osteoblastic cells and osteoclastic
cells. Int J Biochem 25 : 1631–1635, 1993.
Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R &
Westendorf JJ. Histone deacetylase 7 associates with
Runx2 and represses its activity during osteoblast matura-
tion in a deacetylation−independent manner. Journal of
Bone and Mineral Research 23(3) : 361−372, 2008.
Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH,
Ryoo HM, Choi JY, Yoshida M, Nishino N, Oh BC, Lee
KS, Lee YH, Bae SC. Bone morphogenetic protein − 2
stimulates Runx2 acetylation. J Biol Chem 281 : 16502−
16511, 2006.
Jones PA, Issa JP & Baylin S. Targeting the cancer epi-
genome for therapy. Nat Rev Genet 17(10) : 630−641,
2016.
Kang JS, Alliston T, Delston R, Derynck R. Repression of
Runx2 function by TGF−beta through recruitment of class
II histone deacetylases by Smad3. Embo J 24 : 2543–
2555, 2005.
Khan O & La Thangue NB. HDAC inhibitors in cancer bi-
ology : emerging mechanisms and clinical applications.
Immunol Cell Biol 90(1) : 85−94, 2012.
Kim HN, Lee JH, Bae SC, Ryoo HM, Kim HH, Ha H &
Lee ZH. Histone deacetylase inhibitor MS−275 stimulates
bone formation in part by enhancing Dhx36− mediated
TNAP transcription. J bone Miner Res 26 : 2161–2173,
2011.
Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino
N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M,
Horinouchi S & Hayashi H. Cyclic hydroxamic−acid−con-
taining peptide 31, a potent synthetic histone deacetylase
inhibitor with antitumor activity. Cancer Res 61 ( 11 ) :
4459−4466, 2011.
Kurinna S & Barton MC. Cascades of transcription regula-
tion during liver regeneration. Int J Biochem. Cell Biol
43 : 189–197, 2011.
Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J,
WeitzerG, Schuettengruber B, Hauser C, Brunmeir R &
Jenuwein T. Essential function of histone deacetylase 1 in
proliferation control and cdk inhibitor repression. EMBO
J 21 : 2672–2681, 2002.
Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D & Sal-
danha SC. Epigenetic therapy of cancer with histone
deacetylase inhibitors. J Cancer Res Ther 10 : 469 – 478,
2014.
Lee HW, Suh JH, Kim AY, Lee YS, Park SY & Kim JB.
Histone deacetylase 1 − mediated histone modification
regulates osteoblast differentiation. Mol Endocrinol 20 :
2432–2443, 2006.
Lee S., Park J.R., Seo M.S., Roh K.H., Park S.B., Hwang
J.W., Sun B., Seo K., Lee Y.S., Kang S.K., Jung J.W.,
Kang K.S. Histone deacetylase inhibitors decrease prolif-
eration potential and multilineage differentiation capability
of human mesenchymal stem cells. Cell Prolif 42(6) : 711
–720, 2009.
Mann BS, Johnson JR, Cohen MH, Justice R &Pazdur R.
FDA approvalsummary : vorinostat for treatment of ad-
vanced primarycutaneous T−cell lymphoma. Oncologist
12 : 1247−1252, 2007.
McGee−Lawrence ME & Westendorf JJ. Histone deacety-
lases in skeletal development and bone mass maintenance.
Gene 474 : 1–11, 2011.
Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsu-
zaki S, Humphries KM, Richardson JA, Bassel−Duby R
& Olson EN. Maintenance of cardiac energy metabolism
by histone deacetylase 3 in mice. J Clin Invest 118 : 3588
–3597, 2008.
Mostoslavsky R, Chua KF, Lombard DB, Pang WW,
Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S,
Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford
E, Cheng HL, Kennedy C, Nunez N, Bronson R, Fren-
dewey D, Auerbach W, Valenzuela D, Karow M, Hottiger
MO, Hursting S, Barrett JC, Guarente L, Mulligan R,
Demple B, Yancopoulos GD & Alt FW. Genomic insta-
bility and aging−like phenotype in the absence of mam-
malian SIRT6. Cell 124 : 315–329, 2006.
37The Dental Journal of Health Sciences University of Hokkaido 39 2020
（37）
第３９巻１号　　　４Ｃ１５０　１Ｃ１３３／本文　※３１‐１から組体裁変更　ＯＴＦ／０３１～０３９　レビュ　ＳＵＬＴＡ　４Ｃ  2020.07.22 11.01.03  Page 37 
Obri A, Makinistoglu MP, Zhang H & Karsenty G. HDAC
4 integrates PTH and sympathetic signaling in osteoblasts.
J Cell Biol 205 : 771–780, 2014.
Ohtani K & Dimmeler S. Epigenetic regulation of cardio-
vascular differentiation. Cardiovasc Res 90 : 404 – 412,
2011.
Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Roma-
guera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S,
Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L,
Younes A. Phase I study of panobinostat plus everolimus
in patients with relapsed or refractory lymphoma. Clin
Cancer Res 19(24) : 6882−90, 2013.
Peschansky VJ & Wahlestedt C. Non−coding RNAs as di-
rect and indirect modulators of epigenetic regulation. Epi-
genetics 9(1), 3−12, 2014.
Poole RM. Belinostat : first global approval. Drugs 74 :
1543−1554, 2014.
Razidlo DF, Whitney TJ, Casper ME, McGee−Lawrence
ME, Stensgard BA, Li X, Secreto FJ, Knutson SK, Hie-
bert SW &Westendorf JJ. Histone deacetylase 3 depletion
in osteo/chondroprogenitor cells decreases bone density
and increases marrow fat. PloS One 5 : e11492, 2010.
Schroeder TM & Westendorf JJ. Histone deacetylase in-
hibitors promote osteoblast maturation. J Bone Miner Res
20(12) : 2254–2263, 2005.
Schroeder TM, Kahler RA, Li X & Westendorf JJ. Histone
deacetylase 3 interacts with runx2 to repress the osteocal-
cin promoter and regulate osteoblast differentiation. J Biol
Chem 279(40) : 41998−42007, 2004.
Shen J, Montecino M, Lian JB, Stein GS, Van Wijnen AJ,
Stein JL. Histone acetylation in vivo at the osteocalcin lo-
cus is functionally linked to vitamin D−dependent, bone
tissue − specific transcription. J Biol Chem 277 ( 23 ) :
20284–20292, 2002.
Singh N, Gupta M, Trivedi CM, Singh MK, Li L & Ep-
stein JA. Murine craniofacial development requires Hdac3
−mediated repression of Msx gene expression. Dev Biol
377 : 333–344, 2013.
Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T,
Floss T, Goettlicher M, Noppinger PR, Wurst W, Ferrari
VA, Abrams CS, Gruber PJ & Epstein JA. Hdac2 regu-
lates the cardiac hypertrophic response by modulating Gsk
3 beta activity. Nat Med 13 : 324–331, 2007.
van Bokhoven H. Genetic and Epigenetic Networks in In-
tellectual Disabilities. Annu. Rev. Genet. 45 : 81 – 104,
2011.
Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Mead-
ows E, McAnally J, Pomajzl C, Shelton JM, Richardson
JA, Karsenty G & Olson EN. Histone deacelytase 4 con-
trols chondrocyte hypertrophy during skeletogenesis. Cell
119 : 555−566, 2004.
Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wi-
jnen AJ, Lian JB, Yoshida M, Stein GS, Li X. Runx2
(Cbfa1, AML−3) interacts with histone deacetylase 6 and
represses the p21(CIP1/WAF1) promoter. Mol Cell Biol
22 : 7982–7992, 2002.
Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A,
Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC,
Samtsov A, McColloch W, Kim YH. Final results from a
multicenter, international, pivotalstudy of romidepsin in
refractory cutaneous T−cell l ymphoma. J Clin Oncol 28 :
4485−4491, 2010.
Xu Y, Hammerick KE, James AW, Carre AL, Leucht P,
Giaccia AJ & Longaker MT. Inhibition of histone deace-
tylase activity in reduced oxygen environmentenhances
the osteogenesis of mouse adipose−derived stromal cells.
Tissue Eng A(12) : 3697–3707, 2009.
Xu S, De Veirman K, Evans H, Santini GC, Vande Broek
I, Leleu X, De Becker A, Van Camp B, Croucher P, Van-
derkerken K & Van Riet. Effect of the HDAC inhibitor
vorinostat on the osteogenic differentiation of mesenchy-
mal stem cells in vitro and bone formation in vivo. Acta
Pharmacol Sin 34(5) : 699−709, 2013.
Yoshida M, Kijima M, Akita M & Beppu T. Potent and
specific inhibition of mammalian histone deacetylase both
in vivo and in vitro by trichostatin A. J Biol Chem. 5 ;
265(28) : 17174−17179, 1990.
Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux
S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lom-
bard D, Mizeracki A, Matthias G, Alt FW, Khochbin S &
Matthias P. Mice lacking histone deacetylase 6 have hy-
peracetylated tubulin but are viable and develop normally.
Mol Cell Biol 28 : 1688–1701, 2008.
38 Shamima SULTANA et al.／Histone deacetylases and their inhibitors (HDACis) for bone formation and regeneration : A review
（38）






























2010 : Bachelor of Dental Surgery (BDS), Pioneer Dental College & Hospital, Bangladesh
2011 : Visiting Researcher, Division of Clinical Cariology and Endodontology, School of Den-
tistry, Health Sciences University of Hokkaido, Japan.
2013 : Ph.D Fellow, Division of Clinical Cariology and Endodontology, School of Dentistry,
Health Sciences University of Hokkaido, Japan.
39The Dental Journal of Health Sciences University of Hokkaido 39 2020
（39）
第３９巻１号　　　４Ｃ１５０　１Ｃ１３３／本文　※３１‐１から組体裁変更　ＯＴＦ／０３１～０３９　レビュ　ＳＵＬＴＡ　４Ｃ  2020.07.22 11.01.03  Page 39 
